• Bone Health
  • Immunology
  • Hematology
  • Respiratory
  • Dermatology
  • Diabetes
  • Gastroenterology
  • Neurology
  • Oncology
  • Ophthalmology
  • Rare Disease
  • Rheumatology

Poll: Which of These Postpandemic Scenarios Is Most Likely?


The pandemic interrupted health care for many patients and saddled health care institutions with high costs. How might biosimilars improve conditions?

Which of these outcomes is probable in the wake of COVID-19?

Standard injections of pegfilgrastim biosimilars will displace widespread use of the Onpro wearable injector kit.
Use of biosimilars will expand as health care institutions seek to overcome pandemic-related deficits.
Patients presenting with untreated cancers will drive a shift to more biosimilar use.
All of these are likely to occur.
Related Videos
Lakesha Farmer from Cencora
Prerakkumar Parikh, PharmD
Brian Biehn
Chelsee Jensen, PharmD, BCPS
GBW 2023 webinar
Ryan Haumschild, PharmD, MS, MBA
Fran Gregory, PharmD, MBA
Julie Reed
"SEEING EYE TO EYE:  Exploring Different Perspectives on Ophthalmology Biosimilars SEEING EYE TO EYE:  Exploring Different Perspectives on Ophthalmology Biosimilars" with the CfB logo and an image of an eye
Julie Reed, executive director of the Biosimilars Forum
Related Content
© 2024 MJH Life Sciences

All rights reserved.